Could COPD drug hold key to new diabetes treatments?

NCT ID NCT02363335

First seen Mar 17, 2026 · Last updated May 13, 2026 · Updated 5 times

Summary

This study looked at how two drugs, Roflumilast (used for COPD) and Sitagliptin (used for diabetes), affect blood sugar and gut hormones in 29 healthy adults aged 21-55. Participants took the drugs or placebos and had their blood tested after a meal. The goal was to understand how these drugs might help develop new treatments for type 2 diabetes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • National Institute of Aging, Clinical Research Unit

    Baltimore, Maryland, 21224, United States

Conditions

Explore the condition pages connected to this study.